After more than 2 years of relentless campaigning, Enhertu has now been approved for use on the NHS in England for people with HER2-low metastatic breast cancer.
Enhertu was rejected for use on the NHS in England in 2024, but thanks to sustained pressure from supporters like you, the life-extending treatment will now be available to patients in England.
Wales and Northern Ireland usually adopt drug decisions made in England, so we now need both nations to urgently make sure Enhertu is available on the NHS there too, to bring the rest of the UK in line with Scotland, which already approved the drug in 2023.
A huge thank you to everyone who wrote to their MPs! Thanks to you more than 65 MPs supported the Early Day Motion calling for NICE, NHS England and the drug companies to reach a deal, and this played a critical role in reaching this outcome.
This victory is a brilliant example of what we can achieve together. Enhertu will give thousands of people the hope of more time with their loved ones, and this proves the power we have to make a difference for people affected by breast cancer.
To find out more about the campaign and what comes next please sign-up to receive updates or visit our website to read our latest news.